Seqens

CDMO Services: Full service from Preclinical to Industrial production of Small molecules drug substances, Intermediates and RSM, Avanced polymers & Lipids

Poly(lactic acid co-glycolic acid) and poly(caprolactone) copolymers used as functional excipients for controlled and slow drug release (weeks to months) with a single injection.

SEQENS CDMO is a global leader on the production of Active Pharmaceutical Ingredients. The company has over 25 years of experience in developing and producing high-quality Active Pharmaceutical Ingredients using first class R&D and proprietary technology such as biocatalysis to develop unique processes. Mo...

CUSTOM MATERIAL FOR DRUG DELIVERY, MEDICAL MATERIALS & BIOMEDICAL APPLICATIONS

SEQENS offers wide range of products which includes paracetamol. Contact us for more information.

This year at CPHI Barcelona (24–26 October, 2023) we sat down with C-suite executives and HR professionals to discuss the looming talent crisis in the pharmaceutical industry. With hybrid working persisting post-pandemic and a growing skills gap, how can the pharmaceutical supply chain adjust to a changing labour force? 

Discover our plant of Lahr (Germany) where we manufacture custom and generic APIs and intermediates. The site Ecovadis Platinum.

In our packed out content sessions at CPHI Barcelona this year, we focus on some of the hottest topics coming up in the pharma industry, with each track sponsored by a leading expert in the field. 

Discover our offer for advanced polymers and lipids for improved drug delivery and cutting edge medical devices 

Meet with Seqens team members at CPHi, April 25-27, 2023 to learn how we have extended services to rapidly and sustainably advance drug development. VISIT CPHI Booth 441 

Discover our innovation center near Paris 

Seqens open a brand new HPAPI unit in France ! 

>R&D Review – What are the Therapies of the Future?

Cell & Gene Therapies bring a promising future for many serious and rare disease patients. However, manufacturing these treatments represent a lot of challenges and can represent a barrier to the development and thus limiting broader access to these promising cures.
Seqens, with the ongoing acquisition of CELLforCURE, has the ambition to rapidly develop strategic capabilities, unique to Europe, that would:
Encourage closer collaboration between the hospitals, companies and manufacturers in the interest of the patients, Foster a breath of potentially innovative modalities tailored to the changing market, Have the potential to bring new therapies to patients faster.

mRNA vaccines helped us through the COVID-19 pandemic — but they could also help defend against many other infectious diseases. Join Moderna to understand how mRNA can play a key role in future therapies. Learnings from the COVID-19 vaccine and translating mRNA technology to other therapy areas How nanoparticles are paving the way to improve vaccine efficiency

mRNA vaccines helped us through the COVID-19 pandemic — but they could also help defend against many other infectious diseases. Join Moderna to understand how mRNA can play a key role in future therapies.
Learnings from the COVID-19 vaccine and translating mRNA technology to other therapy areas How nanoparticles are paving the way to improve vaccine efficiency

TBC

An overview of current microbiome studies and the potential for improving health outcomes by starting with the gut:
Understanding current challenges in clinical development to help create a strong framework Why does Europe need to take account of US-based studies to help create regulatory pathways?

Networked care is scaling up as an effective model of care for rare diseases, with prevention, diagnosis, care, and treatment administered locally, informed by the body of knowledge and expertise from the whole network.
How a collaborative network can bring about an effective learning process, a key element for success Why patient involvement is crucial to improve success in rare disease outcomes Assessing current test and build practices to help improve manufacturing and development quality of drug products